Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Holding(s) in Company

15th Apr 2016 08:50

RNS Number : 3352V
Oxford Biomedica PLC
15 April 2016
 

For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Oxford Biomedica plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

√

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

√

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation: iii

Aviva plc & its subsidiaries

4. Full name of shareholder(s)  (if different from 3.):iv

Registered Holder:

 

BNY Norwich Union Nominees Limited 15,181,044*

 

Chase (GA Group) Nominees Limited 219,780,219*

State Street Nominees Limited 2,159,221*

 

*denotes direct interest

 

Chase (GA Group) Nominees Limited 20,807,732

 

Chase Nominees Limited 7,566,886

 

Vidacos Nominees Limited 11,939,558

 

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

12 April 2016

6. Date on which issuer notified:

14 April 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

9% to 8% at Direct Interest Level

 (Box 8A&B)

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

GB00066458157

 

283,550,521*

283,550,521*

277,434,660

237,120,484

40,314,176

8.77%

1.49%

 

* Includes Right to Recall Loaned Shares (4,865,559)

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

RIGHT TO RECALL LOANED SHARES

N/A

N/A

5,940,559*

 

*DIRECT INTEREST

0.22%

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

 

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

283,375,219

10.48%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-

 

Aviva Investors Global Services Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

Figures are based the total number of voting rights of 2,702,864,994 as per the Company's Total Voting Rights Announcement of 1 April 2016.

 

14. Contact name:

Tim Watts

15. Contact telephone number:

01865 783000

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUVSBRNKASARR

Related Shares:

Oxford Biomedica
FTSE 100 Latest
Value10,461.95
Change33.68